Investor Webinar – Asundexian

At this event, results from OCEANIC-STROKE, a Phase III study investigating the efficacy and safety of the oral Factor XIa inhibitor Asundexian 50 mg once daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy, will be presented and discussed.

Christoph Koenen, Head of Clinical Development & Operations, Bayer Pharmaceuticals, is going to kick off the event with an overview about the disease characteristics of Secondary Stroke, today’s available therapies, Asundexian’s differentiated structural and pharmacologic profile and the study design.  Next, Ashkan Shoamanesh, Associate Professor of Medicine (Neurology) at McMaster University in Hamilton, Canada, will present key data of OCEANIC-STROKE. Jan Voss, Product Team Lead Asundexian, will then put these results into the context of Asundexian’s overall aspiration as an innovative and advanced therapeutic option in secondary stroke prevention and the next steps to bring this therapy to patients.

The presentations will be followed by a Q&A session.